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ntil the 1990s, it had always been thought that the adult heart could not renew
its cells and that the number of cells present at birth would ‘‘dictate the des-
tiny’’ of this organ through a person’s life.1 According to this idea, myocyte
turnover did not occur, and cells formed during the embryonic and fetal life were
responsible for the preservation of the heart until the end.
Apoptosis, according to this hypothesis, should not occur. The heart would rapidly
lose a number of myocytes, and the remaining cells would not be able to support ven-
tricular function.
The dogma was therefore that the heart cannot regenerate. Anversa challenged this
assumption, leading to a ‘‘paradigm shift’’ in cardiac biology.2
The Expectations
Since Anversa showed that cardiomyocytes undergo apoptosis at a certain rate, the
idea of the heart switched from a ‘‘still-life organ’’ to a self-renewing organ in which
myocyte regeneration occurs. The injured heart may potentially act as a trigger for re-
generative function; the process of repairing the damaged heart is thought to be related
to the balance between regeneration and loss of myocytes. This was further confirmed
recently with highly advanced mouse genetic engineering technologies allowing cel-
lular tracking with a ‘‘fate mapping’’ approach.3 This technique clearly confirmed that
endogenous stem cells refresh adult mammalian cardiomyocytes after myocardial in-
farction or pressure overload. Although an increased number of mitotic cardiomyo-
cytes and cardiac stem cells in the infarcted heart will accelerate the regeneration of
new myocardium, an excessive loss of cardiomyocytes may also be induced by the
ventricular mechanical stress and altered milieu in the infarcted heart. Because the
number of mitotic cardiomyocytes in human beings is very low, a negative balance
between regeneration and loss of myocytes might provide a reasonable explanation
as to why self-repair of the damaged heart is not seen clinically. In line with these con-
cepts, a regenerative medicine approach to the ischemic myocardium with exogenous
cell repopulation is a promising field, but the scientific community largely continues
to debate the controversial results obtained to date. The question may sound provoc-
ative: are there true facts, or only fictions, in the stem cells scenario?
The Reality
Several authors have demonstrated that injections of mixed populations of stem cells
could represent a successful approach to the treatment of ischemic heart disease. The
first clinical experience was described by Menasche´ and colleagues.4 In this prelim-
inary study, the authors treated a single patient with low ejection fraction (35%), aki-
netic segments, and viable and ischemic areas with injection, during heart surgery, of
autologous skeletal myoblast. At 1-year follow-up, ejection fraction had increased and
symptoms improved.
Strauer and associates5 in 2002 enrolled 20 patients with myocardial infarction and
treated 10 of them by intracoronary transplantation of autologous mononuclear bone
marrow cells in addition to standard therapy. After 5 to 9 days from myocardial infarc-
tion, those cells were isolated by Ficoll density separation method from bone marrow
aspirated from the ilium of the patients. Cells were then retransplanted into the in-
farcted area by the use of a balloon angioplasty. After 3 months, comparison between
the control and the cell-treated groups showed interesting differences: the infarctiovascular Surgery c May 2008






Lregion was significantly decreased in the cell-treated group,
as was the perfusion defect, whereas the left ventricle ejection
fraction did not differ between the two groups.
Other studies have been recently published: the TOP-
CARE-AMI trial6 tested safety, feasibility, and potential
effects on parameters of cardiac functions of intracoronary
injections of either bone marrow–derived stem cells or circu-
lating progenitor cells. Invasive follow-up at 4 months by left
ventricular angiography showed significant increase in ejec-
tion fraction and decrease in end-systolic volume in both
groups; at 1 year, a noninvasive follow-up with contrast-
enhanced magnetic resonance, revealed an increased ejec-
tion-fraction and a reduced infarct size.
Chen and colleagues7 treated 34 patients with cell trans-
plantation after percutaneous coronary intervention. They
evaluated the left ventricular function (by echocardiography
and positron emission tomography) 3 and 6 months after
implantation.
Very recently, three more studies were published report-
ing results of stem cell transplantation in acute ischemic set-
tings, adding controversies to the debate.8-10 These studies
were the first prospective, randomized analyses; neverthe-
less, all these investigations had the same limits: the patients
enrolled were few, and the follow-up period was relatively
short. Only the BOOST trial11 reported results with a fol-
low-up as long as 18 months. Unfortunately, the BOOST au-
thors concluded that a single intracoronary injection of bone
marrow–derived cells (BMCs) did not provide long-term im-
provement of left ventricular systolic function after acute
myocardial infarction relative to a randomized control group;
however, this study did suggest an acceleration by BMC ther-
apy (at 6 months) of left ventricular ejection fraction recovery
after acute myocardial infarction.
After the enthusiasm for Anversa results, these prelimi-
nary studies did not fulfill the expectation. Different reasons
have been investigated to explain the controversial efficacy
of stem cell therapy affecting the final translation from basic
science to clinical practice.
The Unresolved Issues
Many important issues are still unresolved:
 Stem cell selection
 Modes of cell delivery
 Ability to retain efficacy
Stem Cell Selection
Different types of adult progenitor cells have been tested, all
autologous to avoid tissue rejection. The first cells to be pro-
posed as surrogate for cardiomyocytes were skeletal muscle
myoblasts, undifferentiated proliferation-competent cells
that serve as precursor to skeletal muscle.12 Human myo-
blasts are isolated from skeletal muscles biopsy samples,
expanded ex vivo, and injected directly into the ventricularThe Journal of Thowall. Bone marrow is, indeed, the most frequently used
source of cells for cardiac repair. It contains a variety of pro-
genitor cells: hematopoietic stem cells, side population cells
(which account for most long-term self-renewal), mesenchy-
mal stem cells, and multipotent adult progenitor cells. Bone
marrow is aspirated, the entire mononuclear cell fraction or
specific subpopulations are obtained, and isolated cells are
injected directly into the heart, without ex vivo expansion.
Peripheral blood–derived progenitor cells are also used.
They are isolated from mononuclear blood cells and selected
ex vivo by culturing in endothelium-specific medium before
reinjection.2
Other cell types have been investigated, further fueling the
expectations: fat tissue–derived multipotent stem cells13 and
amniotic stem cells.14 The latter are fully undifferentiated and
pluripotent, are easily obtained from routine clinical amnio-
centesis specimens, and multiply indefinitely, apparently
without forming tumors. On the one hand, a study from our
group17 has demonstrated that, despite the high expansion
capacity, amniotic fluid–derived mesenchymal cells, at least
in the swine model and in naive, unmanipulated conditions,
are inadequate to support regeneration of cardiogenic cells.
Amniotic fluid–derived mesenchymal cells do not seem to
survive long enough in the periphery of the ischemic lesion,
nor to give rise to a target-specific, committed progeny. On
the other hand, another study from our group,15 with a rat
model of mild cryoinjury, has shown that endothelial cells
and cardiomyocytelike cells originated mostly from trans-
planted amniotic fluid–derived mesenchymal cells, rather
than from bone marrow–derived mesenchymal stem cells.
This finding clearly highlights the extreme difficulty of iden-
tifying suitable animal models for study purpose in regener-
ative medicine and transferring these animal models to
clinical perspectives.
Modes of Cell Delivery
Different techniques of delivery have been proposed to
achieve transplantation of a sufficient number of cells into
the myocardial region and to achieve maximum retention
of cells within the area.2 The three most frequent modes of
delivery are intracoronary, percutaneous endocardial, and
direct intramyocardial during surgery. The intracoronary
injection has the advantage that cells may travel directly
into myocardial regions in which nutrients and oxygen are
preserved, granting engraftment survival. On the other
hand, cellular homing requires migration out of the vessel
into the surrounding tissue. Although bone marrow–derived
stem cells can extravasate, skeletal myoblasts cannot; this can
obstruct microcirculation after intra-arterial administration,
inducing microembolic events.
Direct delivery of cells into satellite scar tissue (endocar-
dially or epicardially) or area of hibernating myocardium (in
chronic ischemia) by needle injection might avoid the risk of
embolic events, but it can cause myocardial wall perforation12racic and Cardiovascular Surgery c Volume 135, Number 5 987
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Lwhen performed endocardially. These techniques also require
additional investigation to prove their efficacy, because the
mechanism of action is not clearly understood.
Stem cells could, on the one hand, promote neoangiogen-
esis and neovascularization and might, on the other hand,
transdifferentiate into cardiomyocytes, depending on the
host environment (acute or chronic ischemia). Nevertheless,
looking at the ability of the transplanted stem cells to trans-
differentiate in cardiomyocytes in different animal models,
the results are strongly controversial.15-17
A paracrine effect has also been postulated. Secretion of
growth factors and cytokines could indirectly promote
survival of cardiomyocytes, inhibiting apoptosis, leading to
mobilization of progenitor cells, and reversing cardiac
remodeling.
A new approach was proposed by Erbs and coworkers18 in
the REPAIR-AMI trial. The authors of this study focused
their attention on the microvascular function, evaluating the
coronary flow reserve in the infarcted artery and in a reference
vessel by intracoronary Doppler ultrasonography at the time
of the study therapy (4 days after acute myocardial infarction)
and at 4 months of follow-up. Coronary flow reserve in the
infarcted artery of the BMC-treated patients increased mark-
edly by 90%, whereas in the control group the increase was
minimal. A considerable reduction in the BMC-treated
patients of the adenosine-induced vascular resistance index
(relative to the control group) further confirmed these results.
The normalization of coronary flow reserve of BMC-
treated patients is consistent with the hypothesis that stem
cells reverse remodeling of the cardiovascular tree in the in-
farcted area. Dysfunctional microvessels in the infarcted area
could be replaced by new and functional vessels, while
growth factors and cytokines released from the injected pro-
genitor cells, in the border area, could promote the growth
and remodeling of the surviving blood vessel.12,18
A promising field is represented by use of biomaterials for
improving the delivery, the adhesion, and the differentiation
of stem cells. Very recently, tissue engineering strategies
have exploited the strategy of cellular transplantation com-
bined with biodegradable biomaterials to create viable myo-
cardial replacement tissue. Biodegradable polymers may act
as temporary scaffolds, providing a template for new viable
tissue and supporting the cells,19 giving them chemical stabil-
ity or degradability, cytocompatibility, cellular adhesion,
proliferation, and mechanical strength.20 Modification of
different parameters, such as physicochemical properties
(surface charge) and surface topography, might influence
and improve cell–material interactions.20,21 The topography
and the type and density of chemical functionalities of
polymer surfaces can be conveniently modified for tissue
engineering by means of cold plasma technology,22 with
the aim of driving eukaryotic cells in in vitro experiments.
Such a controlled surface chemistry of polymers allows
achievement of the ambitious goal of driving the biologic988 The Journal of Thoracic and Cardiovascular Surgery c Mresponses at the material–biologic fluid interface. It has
been shown,23 in fact, that with cold plasma aid it is possible
to drive the behavior of cells in tissue engineering at three
levels:
 the external level, tuning the number and the shapes of the
cells,
 the internal level, the modulation of cytoskeleton plastic-
ity,
 the functional level, the modulation of the functional
expression of cells.
For specific cardiac applications, biomaterials need to be
elastomeric. The material must be able to meet the mechani-
cal demands of cardiac tissue without disintegrating.19 It
must also support angiogenesis and survive the ischemic pe-
riod after infarction. Both extracellular matrix based (colla-
gen type I, extracellular matrix proteins, gelatin meshes, or
modified collagen) and non–matrix-based materials (polysty-
rene beads and collagen threads, polyglycolic acid, caprola-
tone-co-L-lactide24) are currently under investigation.25
This is a promising field that needs to be further eluci-
dated. The studies that have been already conducted have
shown that final results of stem cell–biomaterial combina-
tions for cell-based therapies are multifactorial.
Ability to Retain Efficacy
As mentioned previously, most of the clinical studies have
a limited follow up. Only the BOOST trial has presented re-
sults at 18 months. These results are indeed not encouraging,
considering that recovery in left ventricular ejection fraction
seen at 6-months evaluation was lost at 18 months. The
BOOST authors concluded that stem cells might accelerate
recovery, but they do not maintain it with time. This observa-
tion supports the hypothesis that multiple sequential injec-
tions should be performed at defined intervals.
The End of Hope, or the Beginning of a New Era?
It is clear that a complete understanding of stem cell biology
would have an enormous impact on the ability to optimize
clinical application. Safety of cell therapy is another issue
that needs to be evaluated very carefully. Although no major
side effects have been described to date, it is important to dis-
cuss some potential complications of stem cell injections,
such as an increased risk of arrhythmias, coronary restenosis,
or increased incidence of tumors and teratomas. Menasche´
and coworkers26 described 4 cases of ventricular tachycardia
at 11, 12, 13, and 22 days after transpericardial injection of
skeletal myoblasts. A proarrhythmic effect was also found
by Smits and coworkers27 with myoblasts delivered by
a transvascular route. This effect of skeletal myoblast injec-
tion is probably due either to the lack of electrical coupling
of myoblasts with the cardiac myocytes in the surrounding
area or to a slowed conduction, both of which would promoteay 2008






Lreentrant arrhythmias.28 An intriguing solution to this prob-
lem, proposed by Abraham and colleagues,29 uses myoblasts
genetically engineered to express gap junction protein con-
nexin 43; this has shown decreased arrhythmogenicity.
Coronary restenosis was described by Kang and associ-
ates30 after intracoronary injections of peripheral blood
stem cells in myocardial infarction and stent placement. In-
jection of bone marrow–derived stem cells has also been as-
sociated with increased incidence of new lesions in unstented
vessels. This phenomenon could be due to an increased adhe-
sion capacity of cells when delivered intracoronarily at high
concentration.28
It is nevertheless reassuring that no clinical trials have ever
described an increased incidence of tumor formation. The
major concerns are related to embryonic cells and their poten-
tial to form teratoma, as suggested by Thomson and col-
leagues’ injection of embryonic cells into a skeletal muscle.31
No current therapies have been shown to lead to a reduc-
tion in scar size after myocardial infarction.2 Cell transplanta-
tion has the potential to rebuild the injured heart, regenerating
the damaged myocardium. The injected progenitor cells
should have the ability to replace both morphologically and
functionally the lost myocytes, acquiring contractility and
electrical coupling with the native myocardium. Many ques-
tions need to be addressed for success in this effort. Too many
variables are still present in different studies, and appropriate
cells, appropriate time, and appropriate mode of delivery
have yet to be clarified. Adequate follow-up of patients
must be scheduled to evaluate the effectiveness of cell ther-
apy with time.
As with the initial experience with heart transplantation,
cell therapy, after the pioneering work and initial clamor
arising from the fascinating experiments of Anversa’s labora-
tory, has partially disappointed our expectations. Neverthe-
less, in heart transplantation cyclosporine was eventually
revealed as a key element needed for transplantation to suc-
ceed. Nowadays, we have to understand and identify such
key elements to bring cell therapy from laboratories to pa-
tients. To answer the initial questions, stem cells can defini-
tively work and can ameliorate myocardial function. This is
a proof of concept. How they work and for how long are
the questions that remain to be addressed.
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